{'fraction_non_alphanumeric': 0.04895104895104895, 'fraction_numerical': 0.0, 'mean_word_length': 7.044943820224719, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimer’s disease‐related neurodegeneration

Cerebral atrophy patterns can distinguish normal cognition from Alzheimer’s disease (AD), but neuropathological drivers of these patterns are still not well understood. This study examined baseline cerebrospinal fluid (CSF) biomarkers of AD pathology (amyloid‐beta (Aβ), phosphorylated tau (p‐tau)); neurodegeneration (total tau (t‐tau)); synaptic dysfunction (neurogranin); and neuroaxonal injury (neurofilament light (NFL)) in relation to longitudinal atrophy patterns for two common AD neuroimaging signatures.